ZUSDURI® (Mitomycin intravesical solution)

The FDA on June 12, 2025, approved ZUSDURI® for adult patients with recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC). ZUSDURI® is a product of UroGen Pharma.